Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.54 |
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | GLA | P06280 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.50 |
| ▸ | PPARG | P37231 | 6/20 | 0.50 |
| ▸ | NR2E3 | Q9Y5X4 | 6/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5323077 | 0.80 | ALDH1A1 (0.56) | ERCC5FEN1ALDH1A1KDM4ELMNA | |
| SCHEMBL18774623 | 0.78 | ERCC5 (0.56) | ERCC5FEN1ALDH1A1KDM4ELMNA | |
| SCHEMBL24665384 | 0.78 | ERCC5 (0.49) | ERCC5FEN1ALDH1A1KDM4ELMNA | |
| SCHEMBL2497885 | 0.77 | PIM1 (0.54) | ALDH1A1LMNAHSD17B10TSHRRXFP1 | |
| SCHEMBL22006946 | 0.77 | DAO (0.46) | ALDH1A1LMNAHSD17B10TSHRRXFP1 | |
| SCHEMBL30914138 | 0.77 | MAOB (0.40) | ALDH1A1KDM4ELMNARXFP1PPARG | |
| SCHEMBL1854409 | 0.77 | PIM1 (0.54) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL8691721 | 0.75 | ERCC5 (0.54) | ERCC5FEN1ALDH1A1KDM4ELMNA | |
| SCHEMBL22006356 | 0.75 | PIM1 (0.41) | CA12PARP1CA9PIM1CSNK2A2 | |
| SCHEMBL22006833 | 0.75 | AHR (0.42) | KDM4ECSF1RPDGFRBCA12PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615578-A1 | CYCLIC PYRIDINE DERIVATIVES AS CGAS INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615849-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| CN-120202206-A | Cyclic benzimidazole derivatives as cGAS inhibitors | 勃林格殷格翰国际有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | US | disclosed |
| US-20240189315-A1 | Cyclic Pyridine Derivatives as cGAS Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2024-06-13 | — | — | US | disclosed |
| WO-2024099907-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024099908-A1 | CYCLIC PYRIDINE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-16 | — | — | WO | disclosed |
| US-10361377-B2 | Condensed cyclic compound and organic light emitting device including the same | SAMSUNG SDI CO., LTD. (KR) | 2019-07-23 | — | — | US | disclosed |
| US-20160308142-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-10-20 | — | — | US | disclosed |
| WO-2015105315-A1 | FUSED-RING COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 삼성에스디아이 주식회사 | 2015-07-16 | — | — | WO | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| EP-2364302-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | University of Basel (CH) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | ERCC5 3213/4885FEN1 3147/4885ALDH1A1 3410/4885 |
| US-20160308142-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNE2 | ERCC5 133/4885FEN1 1993/4885ALDH1A1 1905/4885 |
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | CGAS, STING1, IFNAR1 | ERCC5 2747/4885FEN1 490/4885ALDH1A1 815/4885 |
| US-20240189315-A1 | Cyclic Pyridine Derivatives as cGAS Inhibitors | CGAS, STING1, IRF3 | ERCC5 2719/4885FEN1 229/4885ALDH1A1 1257/4885 |
| US-10361377-B2 | Condensed cyclic compound and organic light emitting device including the same | CRY1, CRY2, CCNE2 | ERCC5 122/4885FEN1 2034/4885ALDH1A1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.